Welcome to our dedicated page for Envveno Medical Corporation news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical Corporation stock.
enVVeno Medical Corporation (NASDAQ: NVNO) is an Irvine, California-based, late clinical-stage medical device company developing bioprosthetic, tissue-based venous valves for deep venous disease. This news page aggregates company announcements, press releases, and market disclosures related to enVVeno’s clinical programs, regulatory interactions, and corporate actions.
Readers can follow updates on VenoValve®, enVVeno’s first-in-class surgical replacement venous valve for severe deep chronic venous insufficiency and deep venous insufficiency, as well as enVVe®, its non-surgical, transcatheter-based replacement venous valve for deep venous CVI. News items include information on pivotal clinical studies, health economic analyses, and the company’s discussions with the U.S. Food & Drug Administration, such as the not-approvable letter for the VenoValve PMA application and the subsequent supervisory appeal process.
In addition to clinical and regulatory developments, this feed covers financial and corporate news, including quarterly financial updates, capital-raising arrangements like the at-the-market equity program, and shareholder matters disclosed in proxy statements and Form 8-K filings. Announcements about investor presentations, virtual investor segments, and other outreach events featuring enVVeno’s leadership are also reflected here.
For investors and observers tracking NVNO, the news page offers a centralized view of how enVVeno is progressing its venous valve technologies, responding to regulatory feedback, and managing its capital structure through actions such as a board-approved reverse stock split. Regularly reviewing this page can help users understand the evolving context around enVVeno’s development pipeline, regulatory milestones, and key corporate decisions.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
enVVeno Medical Corporation (NASDAQ: NVNO) has reported significant developments in its VenoValve and enVVe clinical programs. In 2022, the company achieved over half enrollment in the pivotal SAVVE trial of VenoValve, currently totaling 43 patients. The firm ended the year with $39.1 million in cash, remaining on track to sustain operations through the end of 2024. While Q4 cash burn was $3.6 million, net losses for the year declined to $16.5 million. Upcoming milestones include topline safety data from SAVVE expected before the end of 2023 and the initiation of the enVVe trial upon regulatory approval.
enVVeno Medical Corporation (NASDAQ:NVNO) will present at Cowen's 43rd Annual Health Care Conference on March 8, 2023, at 9:10 AM ET. During this event, CEO Robert Berman will discuss the company's innovative solutions for treating venous disease, highlighting their lead product, VenoValve, a first-in-class surgical replacement venous valve aimed at addressing Chronic Venous Insufficiency (CVI). The presentation will be accessible via a live video webcast on the company's website, available for 90 days post-event. enVVeno's advancements, including the upcoming TAVVE trial for their non-surgical enVVe valve, signify a commitment to improving venous care.
enVVeno Medical Corporation (Nasdaq: NVNO) has announced the promotion of Dr. Hamed Alavi to Senior Vice President and Chief Technology Officer. Dr. Alavi has been instrumental in the development of enVVe, a transcatheter-based replacement venous valve, moving it from concept to readiness for human testing in a short timeframe. His role will now focus on integrating innovative technologies, such as artificial intelligence, into existing products and preparing for the commercialization of the VenoValve. These devices aim to improve treatment for chronic venous insufficiency (CVI), a condition affecting leg veins.